



Recommended COVID-19 vaccines for **people without immunocompromise, aged 6 months–4 years**, mRNA vaccines, with vial icons and dosages, May 2023*†





*For administration intervals, see [Table 1](#) in the Interim Clinical Considerations for Use of COVID-19 Vaccines.

†Children who receive the Pfizer-BioNTech COVID-19 Vaccine and transition from age 4 years to 5 years during the 3-dose vaccination series must complete the series they start (i.e., receive the 0.2 mL/3 ug dosage supplied in vials with a maroon cap and label with a maroon border for all 3 doses).

Key



Recommended COVID-19 vaccines for **people without immunocompromise, aged 5 years, mRNA vaccines, with vial icons and dosages, May 2023***†



*For administration intervals, see [Table 1](#) in the Interim Clinical Considerations for Use of COVID-19 Vaccines.



†Children who receive the Pfizer-BioNTech COVID-19 Vaccine and transition from age 4 years to 5 years during the 3-dose vaccination series must complete the series they start (i.e., receive the 0.2 mL/3 ug dosage supplied in vials with a maroon cap and label with a maroon border for all 3 doses).

Children who transition from age 5 years to 6 years during the Moderna vaccination series should receive 2 doses of Moderna COVID-19 Vaccine (0.25 mL/25 ug; dark blue cap and label with a gray border).

Key



Recommended COVID-19 vaccines for **people without immunocompromise, aged 6–11 years, mRNA vaccines, with vial icons and dosages, May 2023**^{*†}




*For administration intervals, see [Table 1](#) in the Interim Clinical Considerations for Use of COVID-19 Vaccines.

†Children who transition from age 5 years to 6 years during the Moderna vaccination series should receive 2 doses of Moderna COVID-19 Vaccine (0.25 mL/25 ug; dark blue cap and label with a gray border).

Key



Recommended COVID-19 vaccines for **people without immunocompromise, aged 12 years and older**, mRNA vaccines, with vial icons and dosages, May 2023*†





*For administration intervals, see [Table 1](#) in the Interim Clinical Considerations for Use of COVID-19 Vaccines.

†People ages 65 years and older have the option to receive 1 additional bivalent mRNA dose at least 4 months after the first dose of a bivalent mRNA vaccine; see [Table 1](#) in the Interim Clinical Considerations for Use of COVID-19 Vaccines.

Key

Moderna
Pfizer-BioNTech
Moderna **OR** Pfizer-BioNTech

Recommended COVID-19 vaccines for **people without immunocompromise, aged 6 months–4 years, mRNA vaccines, May 2023***





*For product- and vaccination history-specific dosages and administration intervals, see [Table 1](#) in the Interim Clinical Considerations for Use of COVID-19 Vaccines.

Key

Moderna
Pfizer-BioNTech
Moderna OR Pfizer-BioNTech

Recommended COVID-19 vaccines for **people without immunocompromise, aged 5 years, mRNA vaccines, May 2023***





*For product- and vaccination history-specific dosages and administration intervals, see [Table 1](#) in the Interim Clinical Considerations for Use of COVID-19 Vaccines.

Key

Moderna
Pfizer-BioNTech
Moderna **OR** Pfizer-BioNTech

Recommended COVID-19 vaccines for **people without immunocompromise, aged 6 years and older, mRNA vaccines, May 2023***



*For product-specific dosages and administration intervals, see [Table 1](#) in the Interim Clinical Considerations for Use of COVID-19 Vaccines.

[†]People ages 65 years and older have the option to receive 1 additional bivalent mRNA dose at least 4 months after the first dose of a bivalent mRNA vaccine; see [Table 1](#) in the Interim Clinical Considerations for Use of COVID-19 Vaccines.

Key

Moderna
Pfizer-BioNTech
Moderna **OR** Pfizer-BioNTech